SecBot SecBot
SECBOTREPLAY Home › Report › MNKD

MNKD · MannKind announced the FDA released it from a postmarketing requirement…

MANNKIND CORP · 8-K filed May 28, 2026 at 08:37 ET

At the news

BULLISHIMPACT 6/10

8-K filed May 28, 2026 at 08:37 ET

MannKind announced the FDA released it from a postmarketing requirement for Afrezza, a five-year pulmonary malignancy study in 8,000-10,000 type 2 diabetes patients, eliminating a major regulatory overhang. The only remaining postmarketing requirement is a pediatric efficacy/safety assessment, with a PDUFA target action date of May 29, 2026. Separately, the company provided a clinical update on the INHALE-1st pediatric study, with data expected in late 2027.

  • FDA released MannKind from a postmarketing requirement to assess pulmonary malignancy risk in 8,000-10,000 Afrezza patients
  • Only remaining postmarketing requirement is pediatric efficacy/safety assessment (sBLA accepted October 2025, PDUFA date May 29, 2026)
  • INHALE-1st study: 8 additional sites activated, up to 100 participants expected, data expected late 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access